Meet our Management Team

Brian Gregg

Chief Executive Officer

As CEO, Mr. Gregg is responsible for managing operations for AmbioPharm and serves on the Board of Directors. Prior to AmbioPharm, he had long and successful career at Bachem, a company specializing in the development and manufacture of peptides and oligonucleotides, where he held for 8 years the position of COO for Bachem Americas. In his extensive career at Bachem, Mr. Gregg has held a variety of positions in peptide manufacturing, quality and compliance, and operations management. His skills include driving business and operational growth and strategic acquisition and integration. He holds an MBA from San Diego State University and a BA in Chemistry from the University of California, San Diego.

Stephen John Kiel

Chief Financial Officer

Mr. Kiel is the Chief Financial Officer of Ambio Pharmaceuticals, the parent company of AmbioPharm. He is also Secretary/Treasurer of the Company and member of the Board since its formation in 2014. He is also primarily responsible for all capital markets activity.
As CFO, Mr. Kiel is responsible for the financial health of the organization, including accounting, financial reporting, cash management, and relations with investors, banks and government. He actively participates in negotiations and contract review,
He was previously a Partner at Deloitte Consulting, one of the nation’s Big Four accounting firms. He holds an MBA from The Ohio State University and was awarded a CPA (now inactive) and Series 7 license.

Thomas Wilson

Chief Commercial Officer

Mr. Wilson brings over 30 years of experience in pharmaceutical operations and commercial strategy and execution. As Chief Commercial Officer at AmbioPharm, he leads business development and commercial operations. Prior to joining AmbioPharm, Mr. Wilson held senior leadership roles at Pfizer and Wyeth, serving as Vice President Contract Manufacturing Business Lead at Pfizer CentreOne. Mr. Wilson holds a Master of Science in Administration & Management from St. Michael’s College and a Bachelor of Science in Physics from St. Joseph’s University. He also served as a Captain in the United States Air Force before beginning his career in the pharmaceutical industry.

Guoqing Zhang

Vice President of Global Research and Development

As Vice President of Global Research and Development, Mr. Zhang is responsible for AmbioPharm’s process development activities at the North Augusta headquarters as well as the Shanghai site. He has more than 20 years’ experience in small- and large-scale peptide synthesis and manufacturing under current Good Manufacturing Practice. Mr. Zhang has expertise with SPPS, LPPS, and hybrid synthesis, successfully employing these approaches for the development of efficient, large-volume commercial peptide manufacturing processes. Additionally, Mr. Zhang establishes synthesis procedures for key building blocks including unnatural amino acids which are not commercially available for inclusion in the manufacture of API peptides. Prior to AmbioPharm, Mr. Zhang spent time at CPC Scientific.

Alexandra Bridges

Vice President of Project Management

As Vice President of Project Management, Ms. Bridges is responsible for Project Management leadership globally. With 30 years of experience in project management, 15 years in the Pharmaceutical industry, and 6 years in the CDMO industry, she has worked for CDMO leaders such as Corden Pharma and Cambrex. Ms. Bridges is a solution-oriented leader, dedicated to developing strong Project Management systems to meet client program needs and deliver superb customer service in the CDMO space. Ms. Bridges holds a Bachelor of Science degree in Chemical Engineering from Clemson University and was awarded a PMP in 2020.

Brant Zell

Senior Quality & Regulatory Advisor

As Senior Quality & Regulatory Advisor, Brant Zell leads the Quality Assurance organization at AmbioPharm globally. Mr. Zell has over 40 years of Quality and Compliance experience with over 13 years in the peptide API industry. He has dedicated his career in ensuring patient safety and health through setting and demanding appropriate current Good Manufacturing Practice. Prior to AmbioPharm, Mr. Zell oversaw Quality at PolyPeptide Laboratories. Mr. Zell is the one of the founders and chair of the Bulk Pharmaceutical Task Force, a group working directly with FDA leadership and representing the industry view on compliance, GDUFA, best practices, and regulatory concerns. Mr. Zell has a Master of Science in Analytical Chemistry and a Master of Business Administration and Technology Management.

Gary T.K. Hu

Senior Vice President of Sales, Asia

Mr. Gary Hu is Senior Vice President of Sales, responsible for sales and business development in Asia including India. Mr. Hu has more than 30 years of experience in the peptide, oligo, and small molecule CDMO industry. Prior to AmbioPharm, he held various leadership roles in business development, strategic alliances, licensing, sales, marketing, project management, and logistics at American Peptide Company and Bachem. In 2018, Mr. Hu established the Bachem K.K. entity in the pharma cluster of Nihonbashi in Tokyo Japan. He also served as board member of American Peptide Company and Bachem Japan K.K.

Nicole Strauss

Vice President of Sales, Americas

Nicole Strauss is Vice President of Sales at AmbioPharm, where she leads commercial strategy and business development across the Americas. In this role, she is responsible for driving growth, expanding strategic partnerships, and helping pharmaceutical and biotechnology companies leverage AmbioPharm’s peptide development and manufacturing capabilities to advance innovative therapies.
Nicole brings over 25 years of experience in pharmaceutical industry, with deep expertise in contract development and manufacturing, commercialization and supply chain strategies, procurement and external partner management. Prior to joining AmbioPharm, she spent over two decades at Pfizer, most recently leading the Pfizer CentreOne Global Development Services team, where she was responsible for building and expanding development service offerings and supporting growth across the CDMO business.
Nicole holds a Bachelor of Science in Chemical Engineering from the Georgia Institute of Technology and a Master of Business Administration from the University of Delaware.

Wen Du

General Manager

Mr. Wen Du brings over 20 years of experience in the biotech and pharmaceutical industry, with deep expertise in supply chain, procurement, manufacturing, and operations across both large pharmaceutical companies and CDMOs. As General Manager of AmbioPharm Shanghai, he oversees site operations and drives strategic growth in alignment with the headquarters’ overall strategy.
Prior to joining AmbioPharm, Mr. Du spent 6.5 years at Lonza, where he served as Senior Director, Head of Operations for Mammalian Mid-Scale at the Switzerland site. He also held key leadership roles at Lonza’s Guangzhou biologics facility, including Manufacturing Director and Supply Chain Director. Earlier in his career, Mr. Du led supply chain operations at Takeda, serving as Supply Chain Director for the Tianjin site and Head of the China Logistics Center.
Mr. Du holds an MBA from Sun Yat-sen University, a Bachelor’s degree in International Economics and Trade from Hubei University of Technology, and a second Bachelor’s degree in Pharmacy from China Medical University.

Sammi Liu

Vice President Finance and HR

Sammi Liu possesses extensive work experience in various finance and HR roles. She joined AmbioPharm in 2013 and progressed from the role of Director of Corporate Finance and Investor Relations to her current position as VP of Finance and HR. Throughout her tenure, she supported the fundraising efforts for series A-1, series A-2, and series B rounds. Currently, she oversees the HR and Finance teams at both North Augusta headquarters and the Shanghai site. Prior to joining AmbioPharm, Ms. Liu worked as a Marketing Specialist at Hang Lung Properties in Shanghai. She holds a Master of Philosophy from Shangdong University, an MBA specialized in Finance from Louisiana State University, and a certificate in Business Analytics from Harvard University.

Mark Brown

Vice President of Accounting

As Vice President of Accounting, Mark Brown is responsible for the Accounting Operations at both the North Augusta headquarters and the Shanghai site. Mr. Brown has an extensive background in international accounting and team leadership. With over 25 years of experience directing diverse international accounting teams in several different industries, he re-joined Ambiopharm in 2024. Prior to this, Mr. Brown held various roles including Vice President of Accounting and Corporate Controller. He holds a Bachelor’s degree in Political Science and a Master’s degree in Accounting from Binghamton University, and is a licensed Certified Public Accountant.